Article
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC.
Future oncology (London, England) - 1 Jun 2018
Pinto Carmine, Normanno Nicola, Orlandi Armando, Fenizia Francesca, Damato Angela, Maiello Evaristo, Tamburini Emiliano, Di Costanzo Francesco, Tonini Giuseppe, Bilancia Domenico, Corsi Domenico, Pisconti Salvatore, Ferrau Francesco, Gori Stefania, Daniele Bruno, Zaniboni Alberto, Soto Parra Héctor, Frassinetti Giovanni Luca, Iaffaioli Rosario Vincenzo, Cassata Antonio, Zampino Maria Giulia, Repetto Lazzaro, Calegari Maria Alessandra, Barone Carlo
Abstract excerpt
The optimal duration and intensity of first-line therapy in metastatic colorectal cancer patients once they have achieved an objective response is controversial. In a molecularly selected RAS and BRAF wild-type (wt) population, this concern is amplified. Once disease control has been achieved with a combination therapy including an anti-EGFR antibody, further exposure both to cytotoxic drugs and targeted therapy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.